Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.
Sonia S AnandWill HiattLeanne DyalRupert M BauersachsScott D BerkowitzKelley R H BranchSebastian DebusKeith A A FoxYan LiangEva MuehlhoferMark R NehlerLloyd P HaskellManesh PatelMichael SzarekSalim YusufJohn William EikelboomMarc P BonacaPublished in: European journal of preventive cardiology (2021)
Among PAD patients, low-dose rivaroxaban plus aspirin is superior to aspirin alone in reducing CV and limb outcomes including acute limb ischaemia and major vascular amputation. This reduction is offset by a relative increase in major bleeding, but not by an excess of fatal or critical organ bleeding. The consistency of findings of these trials supports the use of combination low-dose rivaroxaban plus aspirin in PAD patients across a broad spectrum of disease.
Keyphrases
- low dose
- atrial fibrillation
- end stage renal disease
- high dose
- ejection fraction
- peripheral artery disease
- venous thromboembolism
- chronic kidney disease
- prognostic factors
- pulmonary embolism
- peritoneal dialysis
- cardiovascular events
- antiplatelet therapy
- type diabetes
- adipose tissue
- hepatitis b virus
- percutaneous coronary intervention
- cardiovascular disease
- patient reported outcomes
- acute coronary syndrome
- extracorporeal membrane oxygenation
- lower limb
- aortic dissection